24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for
treatment of vasomotor symptoms (VMS) associated with menopause